Raymond James Financial Inc. Makes New $8.49 Million Investment in Moderna, Inc. (NASDAQ:MRNA)

Raymond James Financial Inc. acquired a new position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 204,249 shares of the company's stock, valued at approximately $8,493,000. Raymond James Financial Inc. owned 0.05% of Moderna at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. abrdn plc grew its stake in shares of Moderna by 28.1% in the fourth quarter. abrdn plc now owns 315,912 shares of the company's stock worth $12,842,000 after purchasing an additional 69,360 shares in the last quarter. Spire Wealth Management lifted its holdings in Moderna by 2,150.4% in the fourth quarter. Spire Wealth Management now owns 23,224 shares of the company's stock worth $966,000 after purchasing an additional 22,192 shares during the period. Proficio Capital Partners LLC grew its position in Moderna by 4,418.9% in the 4th quarter. Proficio Capital Partners LLC now owns 147,360 shares of the company's stock valued at $6,127,000 after buying an additional 144,099 shares in the last quarter. South Dakota Investment Council increased its stake in Moderna by 4.0% during the 4th quarter. South Dakota Investment Council now owns 299,399 shares of the company's stock valued at $12,449,000 after buying an additional 11,500 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Moderna by 2.4% during the 4th quarter. Geode Capital Management LLC now owns 7,241,354 shares of the company's stock worth $300,219,000 after buying an additional 171,774 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

Moderna Stock Performance

MRNA stock opened at $25.74 on Wednesday. The firm has a 50 day simple moving average of $30.61 and a 200 day simple moving average of $39.16. Moderna, Inc. has a 52 week low of $23.15 and a 52 week high of $170.47. The stock has a market cap of $9.95 billion, a P/E ratio of -2.77 and a beta of 2.23.

Analyst Ratings Changes

MRNA has been the topic of a number of research analyst reports. UBS Group lowered their price objective on shares of Moderna from $96.00 to $78.00 and set a "buy" rating on the stock in a research note on Wednesday, February 19th. Barclays downgraded Moderna from an "overweight" rating to an "equal weight" rating and dropped their price objective for the stock from $111.00 to $45.00 in a research note on Tuesday, February 18th. William Blair reaffirmed a "market perform" rating on shares of Moderna in a research note on Thursday, April 17th. Morgan Stanley dropped their price target on shares of Moderna from $39.00 to $32.00 and set an "equal weight" rating on the stock in a research report on Wednesday, April 9th. Finally, Citigroup assumed coverage on shares of Moderna in a report on Thursday, March 13th. They issued a "neutral" rating and a $40.00 target price on the stock. Four investment analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $58.70.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.